Exchange: NASDAQ·Updated 07:45 PM EDT

AXGN News

News
all
press releases
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Zacks
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Zacks
More News
Axogen Q3 2026 Earnings Call Transcript
Axogen (NASDAQ:AXGN) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.read more...
Benzinga
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of +50.00% and +4.17%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
GMED or AXGN: Which Is the Better Value Stock Right Now?
GMED vs. AXGN: Which Stock Is the Better Value Option?
Zacks
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
Zacks
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireVANCOUVER, BC, Oct. 3, 2026VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big...
PR Newswire
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.read more...
Benzinga

Advertisement|Remove ads.